Interested in contributing to Malaria Libre? Take a look at our data, including scaffolds under exploration, challenges, objectives, criteria for next stage transitions and more.
Aryl piperazine |
![]() |
MoA/MoR: Unknown (no cross resistance identified) |
Key features:
|
Challenges: Most compounds associated with high CYP inhibition |
Status: Validated hit |
Next milestone: Identification of early lead |
MMV024406 analogs data |
Aryl imidazole |
![]() |
MoA/MoR:Unknown (no cross resistance identified) |
Key features:
|
Challenges: Poor metabolic stability |
Status: Validated hit |
Next milestone: Identification of early lead |
MMV023227 analogs data |
Available data
Aryl piperazine (MMV024406 analogs)
Aryl imidazole (MMV023227 analogs)
Criteria for next stage transitions